Board of Directors
Kevin Buehler serves as a Director and has more than 30 years of experience in the healthcare and consumer industries. He served as the Division Head of Alcon Laboratories, Inc., a division of Novartis, and previously served as Chief Executive Officer and President of Alcon Inc. Mr. Buehler served on the Alcon Laboratories Board of Directors from 2009-2011. He currently serves on the Executive Committee and Board of Directors for United Way of Tarrant County, Texas.
Steven Dyson is a Director and currently serves as the Chairman of the Board. Mr. Dyson is a Partner and Co-Head of the Healthcare team for Apax Partners in London. In addition to the investment into Acelity, Mr. Dyson has worked on many significant deals with companies such as Unilabs, Capio, General Healthcare Group, Zeneus Pharma, Invent Farma/Neurapharm and most recently Vyaire Medical and Syneron. Prior to joining Apax, Mr. Dyson worked at McKinsey & Co. He currently also serves as Chairman of the Board of Unilabs, Vyaire and Syneron Medical and is a Director of Invent Farma/Neuraxpharm and of General Healthcare Group. Within these Board positions, Mr. Dyson chairs and sits on several compensation, audit and compliance committees.
James G. Carlson
James G. Carlson serves as a Director, and previously served as Chief Executive Officer of Amerigroup from 2007 through 2012, becoming Chairman of the company’s Board of Directors in 2008. Previously, he also served as Amerigroup’s President and Chief Operating Officer. Earlier in his career, Mr. Carlson was an Executive Vice President of UnitedHealth Group. Carlson is also the founder of HealthSpring, a physician group practice management company, and cofounder of Workscape, a software company that later was acquired by ADP. He began his career with the Prudential Insurance Company of America.
Michael Douglas serves as a Director and is a Senior Principal in the Direct Private Equity group of CPP Investment Board (CPPIB), where he has worked on investments across a variety of sectors since he joined CPPIB in 2007. Prior to that, Mr. Douglas worked at Ernst & Young Orenda Corporate Finance. He currently serves on the board of directors of Wilton Re and is also involved with CPPIB’s investment in Antares. He holds a Bachelor of Commerce degree from Queen’s University and is a CFA Charterholder.
Andy Eckert is a Director and serves as Acelity’s President and Chief Executive Officer. Mr. Eckert has held a number of senior executive positions during his career. Prior to joining Acelity, he served as Chief Executive Officer of Valence Health, an emerging leader in value-based healthcare. He previously served as Chief Executive Officer of TriZetto, a leader in payer information technology, and as Chairman and Chief Executive Officer of CRC Health Group, the leading behavioral health treatment provider owned by Bain Capital. Earlier in his career, Mr. Eckert was Chief Executive Officer of Eclipsys Corporation from 2005-2009, and Chief Executive Officer of SumTotal Systems from 2002-2005. He began his career at ADAC Laboratories, including four years as Chairman and Chief Executive Officer until its sale to Philips Medical systems in 2000.
Mr. Eckert has served on a number of corporate boards and is currently the Chairman of Varian Medical Systems, as well as a Director at Becton, Dickinson and Company. He has a Bachelor of Science in Industrial Engineering and a Master of Business Administration, both from Stanford University.
Timothy E. Guertin
Timothy E. Guertin serves as a Director and has more than 35 years of experience in the healthcare industry. Prior to joining the Board of Directors, he held multiple leadership positions at Varian Medical Systems, Inc., including roles of President and Chief Executive Officer. Previously, he also held positions as Chief Operating Officer, Corporate Executive Vice President, and President of Oncology Systems at Varian Medical Systems, Inc. Guertin is currently a member of the Board of Directors for Varian Medical Systems, Inc., Teradyne, Inc., and the Radiation Oncology Institute.
Martin Longchamps serves as a Director and is Managing Director in the Private Equity group of PSP Investments, where he is responsible for the direct investing program in North America. Prior to joining PSP Investments in 2018, Mr. Longchamps served in various executive roles at Transcontinental Inc. since 2010, including Vice President of Corporate Development, and was also previously a partner at private equity firm Edgestone Capital Partners. Mr. Longchamps currently serves as a member of the board of Learning Care and UTA. He has an MBA from Harvard Business School and a Bachelor of Commerce from McGill University.